Reveals effective protein degraders using a solid-phase synthesis platform, suggesting new discovery avenues.
Phenotypic screening offers an effective path for discovering protein degraders, particularly targeting proteins that are poorly characterized or lack sufficient ligand-binding information. Nonetheless, phenotypic protein degrader discovery (PPDD) faces practical hurdles, such as synthetic complexity in generating chemically diverse libraries and difficulties in reliably identifying degradation-driven phenotypes in direct-to-biology (D2B) assays. In response to these challenges, we developed an integrated PPDD platform that combines optimized solid-phase parallel synthesis with a robust D2B screening workflow. Leveraging photocleavable linkers and versatile synthetic strategies, this platform facilitates rapid generation of chemically diverse, ready-to-screen bifunctional molecule libraries requiring minimal purification. As a proof of concept, we synthesized and phenotypically screened 130 cereblon-recruiting molecules, leading to several promising protein degradation-dependent hits. Subsequent hit optimization and target identification validated compound 12-60 as a structurally novel GSPT1 degrader with compelling cellular activity. Overall, our integrated platform represents an efficient and practical toolkit for PPDD, establishing a versatile foundation to accelerate future campaigns and expand the degradable proteome.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: